Terry Rosen

“But you remember when the question came up to Raina about her use of TKI, and she emphasized she's almost like 100% yippee-nevo, and a lot of the academic centers more and more go in that direction where they basically want to get that OS.”

“So first of all, thank you, Terrence, for doing this and thank you for all those of you who are joining us and I think very clearly Castatafan obviously is a center of focus for us, for the world we believe very strongly it's going to be a 5 to 10 billion dollar drug so not surprisingly that question will come up but…”

“We continue to make substantial progress in advancing our portfolio of oncology and immunology programs. Execution throughout the first half of the year has been tremendous, and this tangible productivity will be a focus of today's discussion.”

“So let me just introduce Arcus to those of you out here who might not be as familiar with us. I'll be brief. The company was founded about 10 years ago. We built ourselves around a very strong R&D capability, particularly discovery.”

“We're starting a new era for ARCIS with full ownership of our lead program, Castataphan, our Phase III kidney cancer study, Peak I, enrolling rapidly, a clear path to win in the front line, and a next generation of molecules for inflammation and immunology that can be advanced rapidly into and through development.”